Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats
The DOI matches its Crossref record; 51 of the 57 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that is secreted during meal absorption and is essential for normal glucose homeostasis. However, the relatively low plasma levels and rapid metabolism of GLP-1 raise questions as to whether direct endocrine action on target organs, such as islet cells, account for all of its effects on glucose tolerance. Recently, an alternative neural pathway initiated by sensors in the hepatic portal region has been proposed to mediate GLP-1 activity. We hypothesized that visceral afferent neurons in the portal bed express the GLP-1 receptor (GLP-1r) and regulate glucose tolerance. Consistent with this hypothesis, GLP-1r mRNA was present in the nodose ganglia, and nerve terminals innervating the portal vein contained the GLP-1r. Rats given an intraportal infusion of the GLP-1r antagonist, [des-His(1),Glu(9)] exendin-4, in a low dose, had glucose intolerance, with a 53% higher glucose excursion compared with a vehicle-infused control group. Infusion of [des-His(1),Glu(9)] exendin-4 at an identical rate into the jugular vein had no effect on glucose tolerance, demonstrating that this dose of GLP-1r antagonist did not affect blood glucose due to spillover into the systemic circulation. These studies demonstrate that GLP-1r are present on nerve terminals in the hepatic portal bed and that GLP-1 antagonism localized to this region impairs glucose tolerance. These data are consistent with an important component of neural mediation of GLP-1 action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 receptor was found in nerves that innervate hepatocytes [172], but their presence on human liver or hepatocytes is debated as found by some [169,170] but not others [173,174].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [172]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion
Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/en.140.4.1687 · Cited by 464
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344
AFFERENT IMPULSE DISCHARGES FROM GLUCORECEPTORS IN THE LIVER OF THE GUINEA PIG
Niijima, A. (1969) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1969.tb12914.x · Cited by 302
Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M., & Holst, J. J. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.3.e458 · Cited by 299
Nakagawa, A., Satake, H., Nakabayashi, H., Nishizawa, M., Furuya, K., Nakano, S., Kigoshi, T., Nakayama, K., & Uchida, K. (2004) · Autonomic Neuroscience · doi:10.1016/j.autneu.2003.11.001 · Cited by 295
Strader, A. D., Vahl, T. P., Jandacek, R. J., Woods, S. C., D’Alessio, D. A., & Seeley, R. J. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2004 · Cited by 291
Self-citationExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Burcelin, R., Da Costa, A., Drucker, D., & Thorens, B. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1720 · Cited by 250
Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R., & Niijima, A. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e808 · Cited by 204
Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
Balkan, B., & Li, X. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.4.r1449 · Cited by 200
Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199
Self-citationAnatomy and function of sensory hepatic nerves
Berthoud, H. (2004) · The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology · doi:10.1002/ar.a.20088 · Cited by 197
Glucagon-like peptide-1 is a physiological incretin in rat.
Wang, Z., Wang, R. M., Owji, A. A., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117671 · Cited by 190
Kolligs, F., Fehmann, H.-C., Göke, R., & Göke, B. (1995) · Diabetes · doi:10.2337/diab.44.1.16 · Cited by 185
The Synaptophysin–Synaptobrevin Complex: a Hallmark of Synaptic Vesicle Maturation
Becher, A., Drenckhahn, A., Pahner, I., Margittai, M., Jahn, R., & Ahnert-Hilger, G. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-06-01922.1999 · Cited by 180
Vahl, T. P., Paty, B. W., Fuller, B. D., Prigeon, R. L., & D’Alessio, D. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021479 · Cited by 173
Self-citationHigh Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor
Montrose-Rafizadeh, C., Yang, H., Rodgers, B. D., Beday, A., Pritchette, L. A., & Eng, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21201 · Cited by 171
Seeley, R. J., Blake, K., Rushing, P. A., Benoit, S., Eng, J., Woods, S. C., & D'Alessio, D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01616.2000 · Cited by 169
Self-citationDeterminants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes
Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7743 · Cited by 164
Anini, Y. (2002) · Endocrinology · doi:10.1210/en.143.6.2420 · Cited by 161
Gault, V. A., O'Harte, F. P. M., Harriott, P., Mooney, M., Green, B., & Flatt, P. R. (2003) · Diabetologia · doi:10.1007/s00125-002-1028-x · Cited by 141
Widmann, C., Dolci, W., & Thorens, B. (1995) · Biochemical Journal · doi:10.1042/bj3100203 · Cited by 140
D'Alessio, D. A., Vogel, R., Prigeon, R., Laschansky, E., Koerker, D., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 122
Self-citationQuddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111
Self-citationDeacon, C. F., Plamboeck, A., Møller, S., & Holst, J. J. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00452.2001 · Cited by 103
Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice
Ahrén, B. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00423.2003 · Cited by 99
Thiele, T. E., Seeley, R. J., D’Alessio, D. D., Eng, J., Bernstein, I. L., Woods, S. C., & van Dijk, G. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00584-8 · Cited by 88
Self-citationIonut, V., Hücking, K., Liberty, I. F., & Bergman, R. N. (2005) · Diabetologia · doi:10.1007/s00125-005-1709-3 · Cited by 77
Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs
Nishizawa, M., Moore, M. C., Shiota, M., Gustavson, S. M., Snead, W. L., Neal, D. W., & Cherrington, A. D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00503.2002 · Cited by 69
Pagliassotti, M. J., Myers, S. R., Moore, M. C., Neal, D. W., & Cherrington, A. D. (1991) · Diabetes · doi:10.2337/diab.40.12.1659 · Cited by 65
Dynamic Perifusion to Maintain and Assess Isolated Pancreatic Islets
Sweet, I. R., Cook, D. L., Wiseman, R. W., Greenbaum, C. J., Lernmark, Å., Matsumoto, S., Teague, J. C., & Krohn, K. A. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924111 · Cited by 51
Widmann, C., Dolci, W., & Thorens, B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19957 · Cited by 47
Gut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 31
Self-citationRegulation of Glucagon-Like Peptide-1 Receptor and Calcium-Sensing Receptor Signaling by l-Histidine
Leech, C. A., & Habener, J. F. (2003) · Endocrinology · doi:10.1210/en.2003-0498 · Cited by 30
Iritani, N., Sugimoto, T., Fukuda, H., Komiya, M., & Ikeda, H. (1999) · Journal of Nutrition · doi:10.1093/jn/129.1.46 · Cited by 29
Effect of Somatostatin-28 on Dynamics of Insulin Secretion in Perfused Rat Pancreas
Ensinck, J. W., Laschansky, E. C., Vogel, R. E., & D’Alessio, D. A. (1991) · Diabetes · doi:10.2337/diab.40.9.1163 · Cited by 25
Self-citationHui, H., Yu, R., Bousquet, C., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2001-210979 · Cited by 21
Mueller, N. K., Di, S., Paden, C. M., & Herman, J. P. (2004) · Endocrinology · doi:10.1210/en.2004-0539 · Cited by 18
Self-citationGut peptides in the treatment of diabetes mellitus
Vahl, T. P., & Alessio, D. D. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/eoid.13.3.177.27346 · Cited by 2
Self-citation
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Glp1rmRNA transcripts have been identified in the rat nodose ganglion, which contains vagal afferent nerves, and an immunoreactive GLP-1R protein was detected by western blotting and immunohistochemistry in the portal vein (Vahl et al., 2007).”
BackgroundPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Self-citationRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
“That GLP-1 activates vagal afferent neurons terminating in the wall of the portal vein has been recognized for several years (10).”
BackgroundZhou, J., Martin, R. J., Tulley, R. T., Raggio, A. M., McCutcheon, K. L., Shen, L., Danna, S. C., Tripathy, S., Hegsted, M., & Keenan, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90637.2008 · Cited by 460
Central Control of Body Weight and Appetite
Woods, S. C., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 458
Self-citation
Metadata
- Authors
- Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., & D’Alessio, D. A.
- Affiliations
- University of Cincinnati (US)
- Corresponding author
- D’Alessio, David A.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 148
- Issue
- 10
- Pages
- 4965-4973
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2128181185
- Cited by
- 318
- References
- 57
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 9 · 2021: 20 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 14 · 2016: 21 · 2015: 25 · 2014: 24 · 2013: 32 · 2012: 23
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Cincinnati
- National Institutes of Health (DK17844)
- National Institute of Mental Health (MH 069680)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 54263, DK17844, R01DK054890, DK-54890, T35DK060444)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, glucose tolerance, portal vein, visceral afferent neurons, nodose ganglion, exendin-4, glucose homeostasis, intraportal infusion
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Dose-Response Relationship, Drug, Glucose, Glucose Tolerance Test, Infusions, Intravenous, Liver, Male, Nerve Endings, Nodose Ganglion, Peptides, Portal Vein, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Glucose Intolerance, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.